Chris Nolet

Insider Reports History

Entity
Individual
Location
C/O Revance Therapeutics, Inc., 7555 Gateway Boulevard, Newark, CA
Signature
/s/ Herb Cross, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Chris Nolet:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Revance Therapeutics, Inc. Director Common Stock 43.6K $166K $3.80 May 1, 2024 Direct
POLARITYTE, INC. Director Common Stock 14.4K $11.4K $0.79 Jan 12, 2023 Direct
Revance Therapeutics, Inc. Director Stock Option (Right to buy) 23.5K May 1, 2024 Direct
ArriVent Biopharma, Inc. Director Stock Option (right to buy) 17.9K Jan 25, 2024 Direct
Jasper Therapeutics, Inc. Director Stock Option (right to buy) 7.5K Jun 6, 2024 Direct
POLARITYTE, INC. Director Stock option (right to buy) 6.16K Jan 12, 2023 Direct

Insider Reports Filed by Chris Nolet

Symbol Company Period Transactions Value $ Form Type Date Filed Role
JSPR Jasper Therapeutics, Inc. Jun 6, 2024 1 $0 4 Jun 10, 2024 Director
RVNC Revance Therapeutics, Inc. May 1, 2024 2 $0 4 May 3, 2024 Director
AVBP ArriVent Biopharma, Inc. Jan 25, 2024 1 $0 4 Jan 29, 2024 Director
AVBP ArriVent Biopharma, Inc. Jan 25, 2024 0 $0 3 Jan 25, 2024 Director
JSPR Jasper Therapeutics, Inc. Jun 7, 2023 1 $0 4 Jun 8, 2023 Director
RVNC Revance Therapeutics, Inc. May 3, 2023 2 $0 4 May 5, 2023 Director
PTE POLARITYTE, INC. Jan 12, 2023 2 $0 4 Jan 17, 2023 Director
JSPR Jasper Therapeutics, Inc. Oct 12, 2022 1 $0 4 Oct 13, 2022 Director
PTE POLARITYTE, INC. Oct 1, 2022 1 $0 4 Oct 4, 2022 Director
RVNC Revance Therapeutics, Inc. May 4, 2022 1 $0 4/A May 13, 2022 Director
JSPR Jasper Therapeutics, Inc. Mar 21, 2022 1 $0 4 Mar 23, 2022 Director
JSPR Jasper Therapeutics, Inc. Sep 24, 2021 0 $0 3 Oct 1, 2021 Director
RVNC Revance Therapeutics, Inc. May 5, 2021 2 $0 4 May 7, 2021 Director